stockrowSanofi
SNY Healthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Sanofi (SNY) Gross margin
Sanofi's gross margin over the twelve months to 30 September 2026 was 73.4%, up 1.4 percentage points from fiscal 2025 (72.1%). Over the past ten years it has ranged from 67.5% (fiscal 2020) to 72.1% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 72.1% | 1.89 |
| FY2024 | 70.2% | 0.83 |
| FY2023 | 69.4% | (0.48) |
| FY2022 | 69.8% | 1.11 |
| FY2021 | 68.7% | 1.25 |
| FY2020 | 67.5% | (0.71) |
| FY2019 | 68.2% | 0.23 |
| FY2018 | 68.0% | 0.02 |
| FY2017 | 67.9% | (1.24) |
| FY2016 | 69.2% | 0.49 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 76.2% | 0.69 |
| Jun 2026 | 75.5% | 3.38 |
| Mar 2026 | 72.1% | 2.83 |
| Dec 2025 | 69.3% | (4.83) |
| 39 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG compare | 74.9% |
| SNY Sanofi | 73.4% |
| PFE Pfizer Inc. compare | 73.4% |
| GSK GSK PLC Sponsored ADR compare | 72.6% |
| AMGN Amgen Inc. compare | 70.9% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on SNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement